From: The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials
Cytokines
Included studies
Cases
Chi
I2 %
SMD
95 % CI
P
IL-6
4 [27, 28, 34, 41]
189
28
89 %
−0.32
−1.24,0.6
0.49
IL-10
3 [27, 28, 34]
129
2.63
24 %
1.06
0.64,1.49
<0.00001
TNF-α
4 [28, 29, 34, 35]
190
2.55
0 %
−0.47
−0.76,–0.18
0.002
